GSK has decided to discontinue the development of camlipixant for refractory chronic cough (RCC) after inconsistent Phase 3 trial results indicated limited effectiveness. While the drug showed a favorable safety profile, its inability to significantly improve standard care led to the strategic decision, impacting GSK's pipeline for this specific indication.
GSK's decision to halt the development of camlipixant for refractory chronic cough is a negative catalyst for the company. The inconsistent Phase 3 trial data, particularly the failure of the 50mg dose in CALM-2 and the 25mg dose in both trials, indicates a setback in their pipeline for a potentially significant market. While the drug's safety profile was good, its limited efficacy means it wouldn't offer a substantial improvement over existing treatments, leading to the company's strategic withdrawal. This impacts GSK's short-term growth prospects in the chronic cough market, though camlipixant is still being explored for other indications like IBS, offering a potential long-term offset. Traders should note the immediate negative reaction in GSK's stock price.